During the past 12 months, Acorda Therapeutics's average Book Value per Share Growth Rate was -265.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Acorda Therapeutics was 66.20% per year. The lowest was -82.50% per year. And the median was -1.60% per year.
Competitive Comparison of Acorda Therapeutics's 3-Year Book Growth Rate
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acorda Therapeutics's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's 3-Year Book Growth Rate falls into.
Acorda Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Acorda Therapeutics (OTCPK:ACORQ) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Acorda Therapeutics 3-Year Book Growth Rate Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your